Literature DB >> 11709053

Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.

P B Mullan1, S McWilliams, J Quinn, H Andrews, P Gilmore, N McCabe, S McKenna, D P Harkin.   

Abstract

The introduction of microarray technology to the scientific and medical communities has dramatically changed the way in which we now address basic biomedical questions. Expression profiling using microarrays facilitates an experimental approach where alterations in the transcript level of entire transcriptomes can be simultaneously assayed in response to defined stimuli. We have used microarray analysis to identify downstream transcriptional targets of the BRCA1 (Breast Cancer 1) tumour-suppressor gene as a means of defining its function. BRCA1 has been implicated in the predisposition to early onset breast and ovarian cancer and while its exact function remains to be defined, roles in DNA repair, cell-cycle control and transcriptional regulation have been implied. In the current study we have generated cell lines with tetracycline-regulated, inducible expression of BRCA1 as a tool to identify genes, which might represent important effectors of BRCA1 function. Oligonucleotide array-based expression profiling identified a number of genes that were upregulated at various times following inducible expression of BRCA1 including the DNA damage-responsive gene GADD45 (Growth Arrest after DNA Damage). Identified targets were confirmed by Northern blot analysis and their functional significance as BRCA1 targets examined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709053     DOI: 10.1042/0300-5127:0290678

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  1 in total

1.  Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.

Authors:  C Papadaki; E Tsaroucha; L Kaklamanis; E Lagoudaki; M Trypaki; K Tryfonidis; D Mavroudis; E Stathopoulos; V Georgoulias; J Souglakos
Journal:  Br J Cancer       Date:  2010-12-14       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.